---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-25-053051"
form_type: "8-K"
ticker: "INMB"
cik: "0001711754"
company_name: "Inmune Bio, Inc."
filed_at: "2025-06-10T23:59:59+00:00"
generated_at: "2026-05-19T15:54:20.606937+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# INmune Bio shareholders approve share increase to 6.5M; XPro shows amyloid reduction post-TBI

## Summary
- Stockholders approved Amended 2021 Stock Incentive Plan, increasing shares from 4M to 6.5M; permits accelerated vesting on change of control.
- XPro™ reduced Aβ42, BACE1, and caspase-3 in hippocampus; improved neurological outcomes in transgenic AD mice after TBI.
- Collaboration with Virginia Commonwealth Univ. on TBI-AD link; poster presented at Keystone Symposia on June 10, 2025.
- All director nominees elected; CBIZ CPAs ratified as auditor for FY2025; non-binding say-on-pay and frequency every three years approved.

## SEC filing metadata
- accession: 0001213900-25-053051
- form_type: 8-K
- ticker: INMB
- cik: 0001711754
- company_name: Inmune Bio, Inc.
- filed_at: 2025-06-10T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 5.02, 5.07, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1711754/000121390025053051/0001213900-25-053051-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1711754/000121390025053051/ea0245174-8k_inmune.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-25-053051
- JSON: https://secwatch.observer/filing/0001213900-25-053051.json
- Plain text: https://secwatch.observer/filing/0001213900-25-053051.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.